IL125030A0 - Vitronectin receptor antagonists - Google Patents
Vitronectin receptor antagonistsInfo
- Publication number
- IL125030A0 IL125030A0 IL12503096A IL12503096A IL125030A0 IL 125030 A0 IL125030 A0 IL 125030A0 IL 12503096 A IL12503096 A IL 12503096A IL 12503096 A IL12503096 A IL 12503096A IL 125030 A0 IL125030 A0 IL 125030A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonists
- vitronectin receptor
- vitronectin
- antagonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US936795P | 1995-12-29 | 1995-12-29 | |
| PCT/US1996/020327 WO1997024124A1 (en) | 1995-12-29 | 1996-12-20 | Vitronectin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL125030A0 true IL125030A0 (en) | 1999-01-26 |
Family
ID=21737218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12503096A IL125030A0 (en) | 1995-12-29 | 1996-12-20 | Vitronectin receptor antagonists |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6159964A (zh) |
| EP (1) | EP0906103A1 (zh) |
| JP (1) | JP2000502704A (zh) |
| KR (1) | KR19990076877A (zh) |
| CN (1) | CN1209063A (zh) |
| AU (1) | AU1295597A (zh) |
| BR (1) | BR9612381A (zh) |
| CZ (1) | CZ203898A3 (zh) |
| IL (1) | IL125030A0 (zh) |
| NO (1) | NO983001L (zh) |
| PL (1) | PL327626A1 (zh) |
| TR (1) | TR199801254T2 (zh) |
| WO (1) | WO1997024124A1 (zh) |
| ZA (1) | ZA9610854B (zh) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008214A (en) * | 1994-08-22 | 1999-12-28 | Smithkline Beecham Corporation | Bicyclic compounds |
| CN1209060A (zh) * | 1995-12-29 | 1999-02-24 | 史密丝克莱恩比彻姆公司 | 玻连蛋白受体拮抗剂 |
| JP2000508319A (ja) * | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αｖβ３拮抗薬 |
| US20030125317A1 (en) | 1996-10-02 | 2003-07-03 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
| DE19653645A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6482821B2 (en) | 1996-12-20 | 2002-11-19 | Hoechst Aktiengellschaft | Vitronectin receptor antagonists, their preparation and their use |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| CO4920232A1 (es) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
| US6239138B1 (en) * | 1997-07-25 | 2001-05-29 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
| EP1047425A4 (en) * | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| ES2226413T3 (es) | 1998-02-26 | 2005-03-16 | Celltech Therapeutics Limited | Derivados de fenilalanina como inhibidores de alfa-4 integrinas. |
| EP1061921A4 (en) * | 1998-03-10 | 2005-03-30 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONIST |
| GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
| US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
| GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
| SE9803773D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Pharma Prod | Compounds |
| GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
| CA2358855A1 (en) | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
| PL350057A1 (en) | 1999-02-20 | 2002-11-04 | Merck Patent Gmbh | β-ALANINE DERIVATIVES |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| US6429214B1 (en) | 1999-07-21 | 2002-08-06 | Wyeth | Bicyclic antagonists selective for the αvβ3 integrin |
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
| DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
| GB9929988D0 (en) * | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
| US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
| ATE375330T1 (de) | 2000-04-17 | 2007-10-15 | Ucb Pharma Sa | Enamin-derivate als zell-adhäsionsmoleküle |
| US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
| US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
| DE10028402A1 (de) * | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| AU2001267753A1 (en) | 2000-07-07 | 2002-01-21 | Celltech R And D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
| WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
| US20040058915A1 (en) * | 2000-08-29 | 2004-03-25 | Khanna Ish Kumar | Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| EA200300226A1 (ru) * | 2000-08-30 | 2003-10-30 | Фармасиа Корпорейшн | ГЕМ-ЗАМЕЩЕННЫЕ АНТАГОНИСТЫ ИНТЕГРИНА αvβ3 |
| US6531494B1 (en) * | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
| US6472372B1 (en) | 2000-12-06 | 2002-10-29 | Ortho-Mcneil Pharmaceuticals, Inc. | 6-O-Carbamoyl ketolide antibacterials |
| KR100376088B1 (ko) * | 2001-03-09 | 2003-03-28 | 주식회사 태평양 | 3-아미노프로필코질포스페이트 및 그의 염을 함유한미백화장료 조성물 |
| CZ20033119A3 (cs) | 2001-04-24 | 2005-01-12 | Merck Patent Gmbh | Kombinovaná terapie za použití antiangiogenových činidel a TNF alfa |
| WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
| US6825170B2 (en) | 2001-12-05 | 2004-11-30 | Ortho-Mcneil Pharmaceutical, Inc. | 6-O-acyl ketolide antibacterials |
| GB0130341D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| ATE448312T1 (de) | 2003-09-26 | 2009-11-15 | Merck Serono Sa | Leitsequenzen zur verwendung bei der produktion von proteinen |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| WO2007048127A2 (en) * | 2005-10-20 | 2007-04-26 | The Scripps Research Institute | Fc labeling for immunostaining and immunotargeting |
| AU2006332694A1 (en) * | 2005-12-30 | 2007-07-12 | Alantos Pharmaceuticals, Holding, Inc. | Substituted bis-amide metalloprotease inhibitors |
| EP2335733B1 (en) | 2006-01-18 | 2014-08-06 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
| KR20090108713A (ko) | 2007-01-18 | 2009-10-16 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약 |
| DE102007038250A1 (de) * | 2007-08-13 | 2009-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neues Herstellverfahren |
| JP5637855B2 (ja) | 2007-11-08 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | 蛋白尿症の治療のための方法及び組成物 |
| BRPI0821090B8 (pt) | 2007-12-21 | 2021-05-25 | Ligand Pharm Inc | moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo |
| US8518927B2 (en) | 2009-02-10 | 2013-08-27 | The Scripps Research Institute | Chemically programmed vaccination |
| EP2432779A1 (en) | 2009-05-22 | 2012-03-28 | Exelixis, Inc. | Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases |
| CN102448497A (zh) | 2009-05-25 | 2012-05-09 | 默克专利有限公司 | 在癌症治疗中的西仑吉肽的持续给药 |
| KR20160147007A (ko) | 2014-05-30 | 2016-12-21 | 화이자 인코포레이티드 | 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체 |
| AU2015308350B2 (en) | 2014-08-29 | 2020-03-05 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| KR20190017030A (ko) | 2016-06-13 | 2019-02-19 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Dnmt1의 억제제로서의 치환된 피리딘 |
| EP3589285A4 (en) | 2017-02-28 | 2020-08-12 | Morphic Therapeutic, Inc. | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
| US20180244648A1 (en) | 2017-02-28 | 2018-08-30 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CN108558836A (zh) * | 2018-05-14 | 2018-09-21 | 东南大学 | 一类具有双重作用机制的dpp-4抑制剂及其用途 |
| KR20210065935A (ko) | 2018-08-29 | 2021-06-04 | 모픽 테라퓨틱, 인코포레이티드 | αvβ6 인테그린 억제 |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3450707A (en) * | 1966-12-13 | 1969-06-17 | Sterling Drug Inc | Certain 2-anilino-pyridine derivatives |
| US3627754A (en) * | 1970-05-13 | 1971-12-14 | Hoffmann La Roche | Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts |
| NZ259802A (en) * | 1992-12-21 | 1997-10-24 | Smithkline Beecham Corp | Bicyclic derivatives and pharmaceutical compositions |
| ZA955391B (en) * | 1994-06-29 | 1996-02-09 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
| ZA9610853B (en) * | 1995-12-29 | 1998-04-06 | Smithkline Beecham Corp | Processes and intermediates for preparing pharmaceuticals. |
-
1996
- 1996-12-20 TR TR1998/01254T patent/TR199801254T2/xx unknown
- 1996-12-20 KR KR1019980705004A patent/KR19990076877A/ko not_active Application Discontinuation
- 1996-12-20 EP EP96943818A patent/EP0906103A1/en not_active Withdrawn
- 1996-12-20 PL PL96327626A patent/PL327626A1/xx unknown
- 1996-12-20 CN CN96180114A patent/CN1209063A/zh active Pending
- 1996-12-20 BR BR9612381A patent/BR9612381A/pt unknown
- 1996-12-20 JP JP9524453A patent/JP2000502704A/ja active Pending
- 1996-12-20 AU AU12955/97A patent/AU1295597A/en not_active Abandoned
- 1996-12-20 WO PCT/US1996/020327 patent/WO1997024124A1/en not_active Application Discontinuation
- 1996-12-20 IL IL12503096A patent/IL125030A0/xx unknown
- 1996-12-20 US US09/091,937 patent/US6159964A/en not_active Expired - Fee Related
- 1996-12-20 CZ CZ982038A patent/CZ203898A3/cs unknown
- 1996-12-23 ZA ZA9610854A patent/ZA9610854B/xx unknown
-
1998
- 1998-06-26 NO NO983001A patent/NO983001L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA9610854B (en) | 1998-04-02 |
| AU1295597A (en) | 1997-07-28 |
| CZ203898A3 (cs) | 1999-03-17 |
| NO983001L (no) | 1998-08-26 |
| TR199801254T2 (xx) | 1998-10-21 |
| EP0906103A4 (zh) | 1999-04-07 |
| BR9612381A (pt) | 1999-07-13 |
| US6159964A (en) | 2000-12-12 |
| EP0906103A1 (en) | 1999-04-07 |
| PL327626A1 (en) | 1998-12-21 |
| CN1209063A (zh) | 1999-02-24 |
| KR19990076877A (ko) | 1999-10-25 |
| NO983001D0 (no) | 1998-06-26 |
| WO1997024124A1 (en) | 1997-07-10 |
| JP2000502704A (ja) | 2000-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL125030A0 (en) | Vitronectin receptor antagonists | |
| HUP9900754A3 (en) | Vitronectin receptor antagonists | |
| IL125034A0 (en) | Vitronectin receptor antagonists | |
| EP0767792A4 (en) | VITRONECTIN RECEPTOR ANTAGONISTS | |
| ZA955391B (en) | Vitronectin receptor antagonists | |
| CY2576B1 (en) | Vitronectin receptor antagonists | |
| HU9601529D0 (en) | Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists | |
| HUP0000467A3 (en) | Il-8 receptor antagonists | |
| EP1000031A4 (en) | VITRONECTIN RECEPTOR ANTAGONISTS | |
| ZA9896B (en) | Vitronectin receptor antagonists | |
| IL135189A0 (en) | Vitronectin receptor antagonist | |
| IL135028A0 (en) | Vitronectin receptor antagonists | |
| IL135188A0 (en) | Vitronectin receptor antagonist | |
| HUP9902817A3 (en) | Endothelin receptor antagonists | |
| HU9602054D0 (en) | Endothelin receptor antagonists | |
| EP0854721A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
| EP0841926A4 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
| EP0841916A4 (en) | ENDOTHELINE RECEPTOR ANTAGONISTS | |
| EP0868180A4 (en) | ENDOTHELINM RECEPTOR ANTOGONISTS | |
| SI0957917T1 (sl) | Antagonisti receptorja vitronektina | |
| ZA988562B (en) | Vitronectin receptor antagonists | |
| ZA966593B (en) | Endothelin receptor antagonists | |
| IL141121A0 (en) | Il-8 receptor antagonists |